Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gynecologic Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: Medroxyprogesterone; Medroxyprogesterone Acetate

Criteria

Inclusion Criteria:

• Histologically confirmed primary endometrioid adenocarcinoma of the uterine corpus

• All histologic grades and stages eligible

• Diagnosis by endometrial curettage or biopsy within the past 8 weeks

• Must have the initial tissue block or 16 unstained sections of 5 micron thickness available

• Performance status - GOG 0-3

• No history of thrombophlebitis or thromboembolic disorders

• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

• No prior therapeutic progesterone or anti-estrogen therapy within 3 months before diagnosis

• No concurrent aminoglutethimide

• No prior cancer treatment that would preclude study therapy

• No concurrent bosentan

• No concurrent rifampin